FOLD Q4 2023 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$115M+30.6% YoY

Gross Profit

$104M90.2% margin

Operating Income

-$4M-3.2% margin

Net Income

-$34M-29.4% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+11.2%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$778M

Total Liabilities

$618M

Stockholders' Equity

$160M

Cash & Equivalents

$247M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$115M	$88M	+30.6%
Gross Profit	$104M	$79M	+31.8%
Operating Income	-$4M	-$42M	+91.3%
Net Income	-$34M	-$56M	+39.4%

Geographic Segments

Non-US

$72M62%

UNITED STATES

$43M38%